HIMS
Hims & Hers Health, Inc.
Quarterly revenue, EPS, free cash flow, valuation, and Rule of 40 scores for Hims & Hers Health, Inc..
Hims faces regulatory headwinds as HHS refers the company to DOJ for potential GLP-1 compounding violations. Stock dipped ~2% on the news. The referral cites FDA warnings from September 2025 about 'unapproved and misbranded drugs.' Bears see existential risk if criminal charges materialize. Bulls argue it's manageable regulatory noise — similar cases often settle with fines/reforms. The company still has momentum: $99 oral GLP-1 pill disrupting the $80B market, cancer diagnostics launch, and Q4 earnings Feb 23.
Latest Coverage
HIMS Perfect Storm: FDA, DOJ, and Novo Nordisk Close In — Stock Down 75% From Highs
Hims & Hers faces a triple regulatory and legal assault. FDA crackdown, DOJ criminal referral, and now a Novo Nordisk patent lawsuit have cratered the stock from $68 to $17 in weeks. We break down the compounding threats.
HHS Refers Hims to DOJ for GLP-1 Drug Investigation
HHS refers Hims & Hers to the Department of Justice over potential violations related to compounded GLP-1 weight-loss drugs. Here's what we know and what it means.
HHS refers Hims to DOJ for GLP-1 investigation
HHS General Counsel announces referral to DOJ over potential FD&C Act violations related to compounded GLP-1 drugs. Stock down ~2%. No charges filed yet.
FDA to restrict GLP-1 compounding, names Hims
FDA announces intent to restrict GLP-1 active ingredients for non-approved compounded drugs, explicitly naming Hims as a mass-marketer.
HIMS Enters Cancer Diagnostics with $250 Galleri Test
Hims & Hers launches the Galleri multi-cancer early detection test at 74% off list price. Here's what it means for the stock.
Hims Launches $99 GLP-1 Pill, Undercuts Novo Nordisk by 90%
Hims debuts compounded oral semaglutide at $49-99/month vs $936+ for branded. But without Novo's patented SNAC absorption tech, critics call it a 'waste of $49.' The science and market implications.
Company History
Key Players
Short interest data unavailable for HIMS.
